HEALTH NEWS

Study Title:

Anti-atherosclerosis of oligomeric proanthocyanidins from Rhodiola rosea on rat model via hypolipemic, antioxidant, anti-inflammatory activities together with regulation of endothelial function.

Study Abstract

BACKGROUND:

Rhodiola rosea has been used as a traditional medicine for a long history. Previous studies on oligomeric proanthocyanidins from Rhodiola rosea (OPCRR) have showed that it exhibited significant free radical-scavenging activities, antioxidant activities in aging mice and lipid lowering effects.
HYPOTHESIS/PURPOSE:

We hypothesized that OPCRR can improve the atherosclerosis pathological in rats. In the present study, we investigated the effects of OPCRR on the serum lipid profiles, oxidant stress status, inflammatory cytokines and atherosclerotic mediators, and endothelial dysfunction as well as changes in abdominal aorta of atherosclerosis rats.
METHODS:

The major components of OPCRR were analyzed by using infrared spectrum and HPLC-ESI-MS. The atherosclerosis rat model was induced by high fat and vitamin D3 feeding for 9 weeks and two OPCRR doses (60 and 120 mg/kg b.w.) were orally administered daily for 9 weeks. The rats were then sacrificed and the blood was collected via abdominal aorta and serum was separated by centrifugated for biochemical analysis. Part of the aorta tissues were excised immediately for histopathological examination and western blotting.
RESULTS:

Compared to model group, OPCRR treatments significantly decreased the serum lipid profiles including total cholesterol, total triglycerides, low-density lipoprotein cholesterol (LDL-C) and ox-LDL and increased the high-density lipoprotein cholesterol (HDL-C); significant increased serum antioxidant enzymes (SOD and GSH-Px) and decrease of MDA content as a product of lipid peroxidation; lowered serum levels of TNF-α, IL-1β, IL-6, ICAM-1 and VCAM-1 and enhanced IL-10 level; increased the serum release of nitric oxide and expression of iNOS in aortic, whereas decreased the expression of eNOS.
CONCLUSION:

OPCRR can improve the progress of atherosclerosis by regulation of lipid metabolism, restoring of the antioxidant capacities, and attenuation of pro-inflammatory cytokines and chemcytokines release, and improving the endothelial dysfunction indicated by nitric oxide system.

Copyright © 2018. Published by Elsevier GmbH.
KEYWORDS:

(−)-epigallocatechin gallate; AI; Atherosclerosis; CRI-I; Castelli's Risk Index-I; EGC; EGCG; GSH-Px; HDL-C; HPLC-ESI-MS; ICAM-1; IL-10; IL-1β; IL-6; LDL-C; MCP-1; MDA; NO; Nitric oxide; OPCRR; Proanthocyanidins; Rhodiola rosea; SOD; Serum lipid; TC; TG; TNF-α; VCAM-1; atherogenic index; eNOS; endothelial nitric oxide synthase; epigallocatechin; glutathione peroxidase; high-density lipoprotein cholesterol; high-performance liquid chromatography electrospray ionization-mass spectrometry; iNOS; inducible nitric oxide synthase; intercellular adhesion molecule 1; interleukin 10; interleukin 1β; interleukin 6; low-density lipoprotein cholesterol; malonaldehyde; monocyte chemoattractant protein-1; nitric oxide; oligomeric proanthocyanidins from Rhodiola rosea; superoxide dismutase; total cholesterol; total triglycerides; tumor necrosis factor alpha; vascular cell adhesion molecule 1